profit from every $100 of sales.
$0$100
VolitionRx
$0.20+10.41% today
-97.3% in 1 year
1-year low $0.171-year high $7.60
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What VolitionRx sold, what it kept, and what it did with the cash.
Sales went from $306,392 in 2022 to $1.73 million in 2025, with -$23.4 million of profit last year.
SalesProfit
VolitionRx vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| VolitionRx | No profit yet | ||
 Illumina | 37.9× · Expensive | ||
 Labcorp Holdings | 34.5× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Guardant Health | No profit yet |
AI analysis
An AI analyst reads VolitionRx's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 1 | 1 | 2 | |
| – | – | – | – | |
| -31 | -36 | -27 | -21 | |
| -29 | -34 | -26 | -20 | |
| -30 | -35 | -27 | -23 | |
| -11.00 | -10.00 | -6.20 | -4.40 | |
| – | – | – | – | |
| -9,971.1% | -4,614.1% | -2,182.5% | -1,228.6% | |
| -9,879.1% | -4,555.5% | -2,186.3% | -1,352.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 18 | 28 | 9 | 7 |
| Cash | 11 | 21 | 3 | 1 |
| Total debt | 5 | 6 | 6 | 11 |
| Total liabilities | 21 | 37 | 36 | 42 |
| -3 | -8 | -25 | -34 | |
| 3 | 4 | 4 | 5 | |
| -1,002.2% | – | – | – | |
| 1,175.5% | 452.7% | 108.3% | 68.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -15 | -18 | -26 | -20 | |
| 2 | 1 | 1 | 0 | |
| -17 | -19 | -26 | -20 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 0 | – | |
| 3 | 2 | 1 | 2 |
Valuation
- –
- –
- –
- -0.4×
- 3.5×
- –
- –
- -323.1%
- -381.6%
- 0.0%
Profitability
- 100.0%
- -1,228.6%
- -1,352.2%
- -1,146.1%
- 1,261.8%
- 135.2%
- 72.7%
- -338.4%
- 406.3%
- 583.6%
Growth
- +78.0%
- –
- +25.3%
- –
- +19.3%
Financial health
- –
- -0.33
- 166.1%
- -8.7×
- 0.17
- 0.17
- 0.25
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 7%of 889
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.97 | -0.70 | −38.6% |
| Mar 31, 2026 | -1.00 | -0.70 | −42.9% |
| Nov 13, 2025 | -0.04 | -0.04 | +0.0% |
| Aug 14, 2025 | -0.06 | -0.05 | −20.0% |
| May 15, 2025 | -0.06 | -0.06 | +0.0% |
| Mar 31, 2025 | -0.06 | -0.06 | +0.0% |
| Nov 14, 2024 | -0.07 | -0.07 | +0.0% |
| Aug 14, 2024 | -0.08 | -0.09 | +11.1% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
4/5Passes 4 of 5. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
60Pass
Benjamin Graham
6No pass
Philip Fisher
75Pass
Peter Lynch
–Not enough data
Joel Greenblatt
–Not enough data
Charlie Munger
76Pass
Terry Smith
79Pass
Questions about VolitionRx
Is VolitionRx a good stock to buy?
A business with weak numbers that is not profitable yet. 4 of the 5 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the VolitionRx AI analysis
What does VolitionRx do?
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It is in Medical - Diagnostics & Research.
Does VolitionRx pay a dividend?
No. VolitionRx does not pay a dividend at the moment.
Is VolitionRx stock halal?
No. VolitionRx does not pass our halal screen: its debt is 187% of its market value, at or above the 33% limit. How we check
How has VolitionRx stock done over the past year?
Down 97.3% over the past twelve months, to $0.20. It traded between $0.17 and $7.60 and is 97.3% below its high.
Who are VolitionRx's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Guardant Health. The peers table on this page compares their profit, growth and price with VolitionRx's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.